Sheel N Shah1, Jocelyn R Grunwell1, Ahmad F Mohammad2, Susan T Stephenson2, Gerald B Lee1, Brian P Vickery1, Anne M Fitzpatrick3. 1. Department of Pediatrics, Emory University, Atlanta, Ga; Center for Cystic Fibrosis and Airways Disease Research, Children's Healthcare of Atlanta, Atlanta, Ga. 2. Department of Pediatrics, Emory University, Atlanta, Ga. 3. Department of Pediatrics, Emory University, Atlanta, Ga; Center for Cystic Fibrosis and Airways Disease Research, Children's Healthcare of Atlanta, Atlanta, Ga. Electronic address: anne.fitzpatrick@emory.edu.
Abstract
BACKGROUND: Although blood eosinophils are a frequently used marker of type 2 inflammation in children with asthma, their sensitivity is relatively poor. Additional markers of type 2 inflammation are needed. OBJECTIVE: We hypothesized that plasma concentrations of eosinophil cationic protein (ECP), a marker of eosinophil activation, would be useful for detection of type 2 inflammation and would predict poorer asthma outcomes over 1 year. METHODS: Children and adolescents 6 through 17 years (N = 256) with confirmed asthma completed a baseline visit and a follow-up visit at 12 months. A subset also underwent systemic corticosteroid responsiveness testing with intramuscular triamcinolone. Outcome measures at 12 months included uncontrolled asthma, lung function, and asthma exacerbations treated with systemic corticosteroids. RESULTS: Plasma ECP concentrations ranged from 0.03 to 413.61 ng/mL (median, 6.95 ng/mL) and were consistently associated with other markers of type 2 inflammation. At baseline, children in the highest ECP tertile had poorer asthma control, more airflow limitation, and more exacerbations, but also had greater symptom improvement with intramuscular triamcinolone. At 12 months, associations between the highest ECP tertile and exacerbations, but not lung function or asthma control, persisted after covariate adjustment. However, the sensitivity of ECP was modest and was not markedly different from that of blood eosinophil counts. CONCLUSION: Plasma ECP concentrations may be a useful marker of type 2 inflammation in children and may help identify those children at highest risk for recurrent exacerbations who could benefit from corticosteroid treatment. However, additional markers may be needed to improve sensitivity for outcome detection.
BACKGROUND: Although blood eosinophils are a frequently used marker of type 2 inflammation in children with asthma, their sensitivity is relatively poor. Additional markers of type 2 inflammation are needed. OBJECTIVE: We hypothesized that plasma concentrations of eosinophil cationic protein (ECP), a marker of eosinophil activation, would be useful for detection of type 2 inflammation and would predict poorer asthma outcomes over 1 year. METHODS: Children and adolescents 6 through 17 years (N = 256) with confirmed asthma completed a baseline visit and a follow-up visit at 12 months. A subset also underwent systemic corticosteroid responsiveness testing with intramuscular triamcinolone. Outcome measures at 12 months included uncontrolled asthma, lung function, and asthma exacerbations treated with systemic corticosteroids. RESULTS: Plasma ECP concentrations ranged from 0.03 to 413.61 ng/mL (median, 6.95 ng/mL) and were consistently associated with other markers of type 2 inflammation. At baseline, children in the highest ECP tertile had poorer asthma control, more airflow limitation, and more exacerbations, but also had greater symptom improvement with intramuscular triamcinolone. At 12 months, associations between the highest ECP tertile and exacerbations, but not lung function or asthma control, persisted after covariate adjustment. However, the sensitivity of ECP was modest and was not markedly different from that of blood eosinophil counts. CONCLUSION: Plasma ECP concentrations may be a useful marker of type 2 inflammation in children and may help identify those children at highest risk for recurrent exacerbations who could benefit from corticosteroid treatment. However, additional markers may be needed to improve sensitivity for outcome detection.
Authors: M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger Journal: Eur Respir J Date: 2005-08 Impact factor: 16.671
Authors: Thomas B Casale; Allan T Luskin; William Busse; Robert S Zeiger; Benjamin Trzaskoma; Ming Yang; Noelle M Griffin; Bradley E Chipps Journal: J Allergy Clin Immunol Pract Date: 2018-05-22
Authors: Jacqueline A Pongracic; Rebecca Z Krouse; Denise C Babineau; Edward M Zoratti; Robyn T Cohen; Robert A Wood; Gurjit K Khurana Hershey; Carolyn M Kercsmar; Rebecca S Gruchalla; Meyer Kattan; Stephen J Teach; Christine C Johnson; Leonard B Bacharier; James E Gern; Steven M Sigelman; Peter J Gergen; Alkis Togias; Cynthia M Visness; William W Busse; Andrew H Liu Journal: J Allergy Clin Immunol Date: 2016-10 Impact factor: 10.793
Authors: Robert A Nathan; Christine A Sorkness; Mark Kosinski; Michael Schatz; James T Li; Philip Marcus; John J Murray; Trudy B Pendergraft Journal: J Allergy Clin Immunol Date: 2004-01 Impact factor: 10.793
Authors: Pablo Rodriguez Del Rio; Andrew H Liu; Magnus P Borres; Eva Södergren; Fabio Iachetti; Thomas B Casale Journal: Int J Mol Sci Date: 2022-03-31 Impact factor: 5.923